Glyscend, Inc.
Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity. They focus on innovative polymer therapies that mimic the effects of metabolic surgery without invasive procedures, leveraging their MCP platform to target mechanisms inside the GI tract for treating metabolic and chronic conditions.
Industries
Nr. of Employees
small (1-50)
Glyscend, Inc.
Products
Oral polymer duodenal exclusion therapeutic (lead clinical candidate)
An orally‑administered, gut‑restricted polymer designed to interact with duodenal mucus to form a reversible barrier that modulates mucosal signaling and metabolic physiology; developed for treatment of type 2 diabetes and obesity.
Oral polymer duodenal exclusion therapeutic (lead clinical candidate)
An orally‑administered, gut‑restricted polymer designed to interact with duodenal mucus to form a reversible barrier that modulates mucosal signaling and metabolic physiology; developed for treatment of type 2 diabetes and obesity.
Expertise Areas
- Oral polymer therapeutics
- GI‑targeted drug development
- Metabolic disease therapeutics (type 2 diabetes and obesity)
- Preclinical metabolic disease models
Key Technologies
- Mucus‑complexing polymer therapeutics
- pH‑dependent GI targeting
- Surface plasmon resonance (SPR)
- Rodent metabolic disease models
News & Updates
Glyscend announced the initiation of a Phase 2 clinical trial of GLY-200 for obesity, after demonstrating reductions in glucose, lipids, body weight, food intake, and appetite in a previous study.
A study published in Diabetes, Obesity and Metabolism demonstrating the safety and biomarker effects of GLY-200.
Top-line results from a Phase IIa study showing promising safety and efficacy of GLY-200 in patients with Type 2 diabetes.
Glyscend closed a $20.5 million Series A financing to develop its novel oral polymer therapy.
Glyscend announced the initiation of a Phase 2 clinical trial of GLY-200 for obesity, after demonstrating reductions in glucose, lipids, body weight, food intake, and appetite in a previous study.
A study published in Diabetes, Obesity and Metabolism demonstrating the safety and biomarker effects of GLY-200.
Top-line results from a Phase IIa study showing promising safety and efficacy of GLY-200 in patients with Type 2 diabetes.
Glyscend closed a $20.5 million Series A financing to develop its novel oral polymer therapy.